Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Papillomavirus Infections 1Neoplasm Metastasis 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Carcinoma in Situ 1Carcinoma 1Burkitt Lymphoma 1

Interventions

Fluorouracil 2Colposcopy 2motexafin lutetium 1fludarabine phosphate 1fludarabine 1aldesleukin 1Vaginal Smears 1Respiratory Function Tests 1Prochlorperazine 1Positron-Emission Tomography 1Polymerase Chain Reaction 1Photochemotherapy 1Papanicolaou Test 1Ondansetron 1O(6)-codeine methyl ether 1Meperidine 1Magnetic Resonance Imaging 1Loperamide 1Isotretinoin 1Interleukin-2 1Innovar 1Indomethacin 1Imiquimod 1Hydroxyzine 1Granisetron 1Fluorophotometry 1Electrocardiography 1Droperidol 1Doxylamine 1Diphenoxylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Uterine Cervical Dysplasia × Ondansetron × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡